论文部分内容阅读
目的观察香丹注射液联合TP方案化疗治疗中晚期非小细胞肺癌(NSCLC)的临床疗效及不良反应。方法将90例中晚期非小细胞肺癌患者随机分为两组,治疗组(48例)采用香丹注射液加TP方案治疗,对照组(42例)采用单纯TP方案化疗,观察两组临床疗效。结果治疗组和对照组的有效率分别为47.9%和28.6%(P<0.05);生活质量改善治疗组60.4%,对照组40.5%,两组比较差异有统计学意义(P<0.05)。结论香丹注射液联合TP方案治疗晚期NSCLC是是一种安全、合理、有效、廉价的方法,可以作为一线方案推荐临床推广。
Objective To observe the clinical efficacy and adverse reactions of Xiangdan Injection combined with TP regimen in the treatment of advanced non-small cell lung cancer (NSCLC). Methods Ninety patients with advanced non-small cell lung cancer were randomly divided into two groups. The treatment group (48 cases) was treated with Xiangdan injection plus TP regimen, while the control group (42 cases) with simple TP regimen. The clinical efficacy . Results The effective rates of the treatment group and the control group were 47.9% and 28.6%, respectively (P <0.05). The quality of life improvement was 60.4% in the treatment group and 40.5% in the control group, with significant difference between the two groups (P <0.05). Conclusion Xiangdan injection combined with TP regimen in the treatment of advanced NSCLC is a safe, reasonable, effective and inexpensive method, which can be recommended as first-line clinical promotion.